Roche's enicepatide met both primary endpoints in a 447-patient Phase II trial, delivering a 2.65% HbA1c reduction and 15.5% weight loss at the 24 mg dose over 48 weeks. The dual GLP-1/GIP agonist showed no weight-loss plateau and a 2.0% discontinuation rate from adverse events. Roche plans Phase III glycemic-control and cardiovascular outcomes trials in the first half of 2027.
Roche said its experimental drug enicepatide lowered blood sugar by 2.65% and body weight by 15.5% at 48 weeks in adults with type 2 diabetes and overweight or obesity, hitting both primary endpoints of a Phase II study.
"We are highly encouraged by the efficacy demonstrated by enicepatide in this Phase II study, including the meaningful proportion of patients reaching normalized glucose levels within less than a year of treatment," Levi Garraway, chief medical officer and head of Global Product Development at Genentech, a member of the Roche Group, said. "Combined with sustained weight loss, enicepatide offers a potential best-in-disease profile capable of reducing and preventing complications as well as enhancing metabolic health for people living with type 2 diabetes."
The trial, designated CT-388-104, randomized 447 adults to once-weekly subcutaneous enicepatide or placebo for 48 weeks. Patients titrated to the highest 24 mg dose recorded an HbA1c reduction of 2.65% from a baseline of 8.1%. Among those with poor glycemic control at entry — an HbA1c above 8.5% — the 24 mg arm produced a 4.13% reduction. By week 48, 90% of the 24 mg cohort reached the 6.5% HbA1c threshold that defines diabetes, and 62% achieved normoglycemia below 5.7%, returning blood glucose to a non-diabetic range. Weight loss of 15.5% at 24 mg showed no demonstrable plateau at the 48-week mark.
Safety tracked the established incretin class. Adverse events were predominantly mild-to-moderate gastrointestinal effects, and discontinuation due to adverse events ran at 2.0% across enicepatide arms versus 0.0% on placebo. Roche reported no new safety signals.
Enicepatide is a dually biased GLP-1/GIP receptor agonist designed to activate both receptors with minimal to no beta-arrestin recruitment, which limits receptor internalization and the desensitization that follows. Roche argues that profile supports prolonged pharmacological activity relative to molecules that recruit beta-arrestin more readily.
Roche is running two Phase III studies in chronic weight management, ENITH-1 and ENITH-2, and plans to start a Phase III glycemic-control program plus cardiovascular outcomes trials in the first half of 2027. The company has not disclosed a regulatory submission date or a peak sales estimate for the drug.
The readout puts Roche in direct contention with Novo Nordisk's semaglutide (Wegovy, Ozempic) and Eli Lilly's tirzepatide (Zepbound, Mounjaro), the two products that have defined the incretin market. Roche shares closed at 364.80 Swiss francs on the SIX Swiss Exchange before the announcement, up 2.24%, and the stock has gained 10.18% year to date. The mean analyst consensus stands at outperform across 19 analysts, with an average target price of 375.34 francs, implying 2.89% upside from that close.
For holders, the data support the pipeline case that has driven Roche's re-rating this year, but Phase II efficacy in diabetes does not settle the commercial question. Novo Nordisk and Eli Lilly hold years of manufacturing scale, payer contracts and cardiovascular outcomes labels that Roche does not yet have. The next hard test is the ENITH-1 and ENITH-2 weight-management readouts, followed by the glycemic-control and cardiovascular outcomes trials slated to begin in the first half of 2027 — the studies that would determine whether enicepatide can win label claims beyond weight loss.
This article is for informational purposes only and does not constitute investment advice.
